Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

doi:10.1080/17512433.2021.1894129

	Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
	Wang, Zeng 1; Jiang, Liyu 2; Yan, Hao 2; Xu, Zhifei 2; Luo, Peihua 2
刊名	EXPERT REVIEW OF CLINICAL PHARMACOLOGY
	2021-03-01
关键词	Adverse events chronic myeloid leukemia management mechanisms molecular target nilotinib
ISSN号	1751-2433
DOI	10.1080/17512433.2021.1894129
通讯作者	Luo, Peihua(xzfzjut@zju.edu.cn)
英文摘要	Introduction: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly diagnosed chronic myeloid leukemia (CML) patients and the second-line treatment of most CML patients who are resistant or intolerant to prior therapy that includes imatinib. In addition to common adverse reactions, long-term use of nilotinib shows some toxicities that are different from those of occurring during other BCR/ABL TKI treatments, such as cardiovascular toxicity. It is life-threatening, which would affect not only the choice of initial treatment of CML patients but also the safety of long-term medication. Areas covered: Through searching literature and reports from PubMed and clinical trials, here we review a profile of the adverse effects induced by nilotinib. We also discuss the potential molecular toxicological mechanisms and clinical management, which may provide strategies to prevent or intervene the toxicity associated with nilotinib. Expert opinion: Severe adverse effects associated with nilotinib limit its long-term clinical application. However, the exact mechanisms underlying these toxicities remain unclear. Future research should focus on the developing strategies to reduce the toxicities of nilotinib as well as to avoid similar toxicity in the development of new drugs.
资助项目	National Natural Science Foundation of China[82003862] ; 1022 Talent Training Program of Zhejiang Cancer Hospital
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	TAYLOR & FRANCIS LTD
WOS记录号	WOS:000624006200001
资助机构	National Natural Science Foundation of China ; 1022 Talent Training Program of Zhejiang Cancer Hospital
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/120958]
专题	中国科学院合肥物质科学研究院
通讯作者	Luo, Peihua
作者单位	1.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Canc & Basic Med ICBM, Dept Colorectal Pharm,Canc Hosp,Zhejiang Canc Hos, Hangzhou, Peoples R China 2.Zhejiang Univ, Ctr Drug Safety Evaluat & Res, Coll Pharmaceut Sci, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Zeng,Jiang, Liyu,Yan, Hao,et al. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY,2021.
APA	Wang, Zeng,Jiang, Liyu,Yan, Hao,Xu, Zhifei,&Luo, Peihua.(2021).Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies.EXPERT REVIEW OF CLINICAL PHARMACOLOGY.
MLA	Wang, Zeng,et al."Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies".EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021).